Europe Biosimilars Market Industry Insights Show Rising Investment in R&D

The European biosimilars market is experiencing rapid expansion, fueled by the growing demand for cost-effective treatments, the expiration of biologic patents, and regulatory support. This market is anticipated to grow at a CAGR of 15.3%, from USD 16.4 billion in 2026 to USD 44.3 billion by 2033. Biosimilars, which are biologic medical products highly similar to already approved reference biologics, are gaining traction due to their potential to significantly lower healthcare costs while maintaining similar safety and efficacy profiles to their reference counterparts. Their increasing prevalence across a variety of therapeutic areas, particularly in oncology, immunology, and autoimmune diseases, underscores their growing importance in Europe’s healthcare systems.

In Europe, the adoption of biosimilars is further accelerated by strong support from the European Medicines Agency (EMA) and favorable government policies, which encourage their integration into public health programs. Moreover, as the patent expirations of numerous blockbuster biologics create an opening for biosimilars to enter the market, these products provide significant opportunities for savings and broader access to essential therapies.

Key Highlights from the Report:

• The European biosimilars market is projected to reach USD 44.3 billion by 2033.
• Oncology biosimilars are forecasted to register a CAGR of 13.7% through 2033.
• Hospital pharmacies are projected to be the fastest-growing distribution channel, with a CAGR of 14.2%.
• Germany is expected to dominate the market with a CAGR of 15% through 2033.
• Biosimilars have generated savings exceeding €50 billion since 2006, with €10 billion saved in 2023 alone.
• The autoimmune disease segment dominates the market with approximately 36% market share.

Market Segmentation

The Europe biosimilars market is segmented by product type, end-user, and therapeutic area.

Product Type:
Biosimilars are broadly categorized into monoclonal antibodies, insulin and growth hormones, and recombinant proteins. The monoclonal antibody segment is expected to continue its dominance, driven by the growing adoption of biosimilars for cancer therapies and autoimmune diseases. Biosimilars of monoclonal antibodies, such as rituximab, trastuzumab, and bevacizumab, have gained traction due to the growing incidence of cancer and the rising demand for affordable treatments.

End-User:
Hospital pharmacies play a central role in the distribution of biosimilars, especially for complex biologics administered in hospital settings. As treatment protocols for chronic diseases such as rheumatoid arthritis, Crohn’s disease, and cancer evolve, hospital pharmacies are becoming key players in the dispensing and monitoring of biosimilars. The growing adoption of value-based care models and centralized procurement systems in European hospitals further propels the hospital pharmacy market segment.

Therapeutic Area:
The therapeutic areas that have witnessed significant growth in biosimilars include oncology, immunology, autoimmune diseases, and diabetes. Among these, oncology is projected to be the fastest-growing segment, with a robust CAGR of 13.7%. Autoimmune diseases, such as rheumatoid arthritis and psoriasis, have been the leading therapeutic categories, contributing to the overall growth of the biosimilars market, owing to the high cost of reference biologics and the increasing demand for affordable treatment alternatives.

Regional Insights

Europe is one of the largest markets for biosimilars globally. Within Europe, Germany is expected to lead the market due to its strong healthcare infrastructure and the presence of prominent biosimilar manufacturers such as Sandoz AG. Germany has been at the forefront of biosimilar adoption, supported by its efficient reimbursement systems and government policies that encourage the use of cost-effective biologic alternatives. Other key European countries such as the UK, France, and Italy are also contributing to the growing market share of biosimilars, though the rate of adoption varies.

In some countries, biosimilars have been more slowly integrated into healthcare systems due to conservative prescribing practices and the minimal pricing difference between originator biologics and their biosimilar counterparts. However, in Scandinavia and Eastern Europe, where healthcare systems are more cost-conscious, biosimilars are gaining a more substantial foothold. The increasing awareness of the cost-saving potential of biosimilars is helping to drive uptake in these regions, further contributing to the market's growth.

Read More: https://www.persistencemarketresearch.com/market-research/europe-biosimilars-market.asp

Market Drivers

Several factors are driving the growth of the biosimilars market in Europe. First and foremost, patent expirations of blockbuster biologics are creating significant opportunities for biosimilars to enter the market. As biologic patents expire, biosimilars present a more affordable alternative, making them an attractive option for healthcare providers and patients alike. The rising cost of healthcare and the financial burden it imposes on European healthcare systems are also motivating the shift towards cost-effective biosimilars.

Another major driver is wider reimbursement and pricing approvals across Europe. Many European countries, including the UK, Germany, and France, have introduced favorable reimbursement policies for biosimilars, enabling greater access to these therapies for patients. This is helping reduce the overall cost of treatment and providing patients with access to high-quality, affordable options. Additionally, regulatory support from the EMA has accelerated the approval and market entry of biosimilars, encouraging manufacturers to invest in biosimilar development.

Market Restraints

Despite the promising growth trajectory of the biosimilars market, there are significant challenges that need to be addressed. Intellectual property (IP) and patent litigation represent substantial barriers to market entry. Originator biologics often have complex patent portfolios, and patent disputes can delay the approval and commercial launch of biosimilars. Furthermore, evergreening practices, where originator companies file new patents to extend exclusivity, further limit the market potential for biosimilars.

Another constraint is the slow adoption of biosimilars in some European countries, which is due to a variety of factors. Conservative prescribing practices, lack of awareness among healthcare professionals, and concerns about the clinical effectiveness of biosimilars have hindered their uptake in certain regions. In some countries, the pricing difference between originator biologics and biosimilars is minimal, which diminishes the incentive for healthcare providers to switch to biosimilars. Overcoming these hurdles requires education, awareness campaigns, and further regulatory incentives to drive adoption.

Market Opportunities

The Europe biosimilars market presents several opportunities for growth. Biosimilar-reference biologic switching is one of the most significant opportunities. As healthcare systems seek ways to reduce costs, the ability to switch patients from originator biologics to biosimilars could provide substantial savings. The EMA’s support for interchangeability of biosimilars with their reference biologics further enhances this opportunity. This trend is particularly important for chronic disease management, where patients require long-term treatment.

Another promising opportunity lies in the expansion of biosimilars into non-oncology therapeutic areas. While oncology has been the primary focus for biosimilars, there is growing interest in developing biosimilars for conditions like autoimmune diseases, diabetes, and inflammatory disorders. These areas have large patient populations where biologic treatments are expensive, creating an ideal market for affordable biosimilar alternatives. Expanding into these therapeutic areas can broaden the reach of biosimilars, making them accessible to more patients across Europe.

Company Insights

Several key players dominate the European biosimilars market. These include both established pharmaceutical giants and specialized biosimilar manufacturers. The major companies involved in the market include:

• Sandoz
• Amgen
• Samsung Biologics
• Biogen
• Celltrion
• Pfizer
• Biocon
• Viatris (Mylan Pharmaceuticals)
• Coherus BioSciences
• Boehringer Ingelheim
• Eli Lilly
• Bio-Thera Solutions

Key Developments in the Market

1. Sandoz launched Afqlir®, a biosimilar to Regeneron/Bayer’s Eylea®, in the UK in November 2025, with plans for broader European expansion by 2026.

2. In July 2024, Apotex Inc. partnered with Coherus Biosciences to license toripalimab, an anti-PD-1 monoclonal antibody for oncology, marking a major expansion into biologics.

Conclusion

The Europe biosimilars market is poised for substantial growth over the next decade. With factors such as patent expirations, regulatory support, cost-effective treatment options, and expanding therapeutic areas driving the market forward, biosimilars offer a promising solution to Europe’s healthcare challenges. As adoption rates increase, especially in non-oncology therapeutic areas, the market is expected to expand rapidly, benefiting both healthcare systems and patients. However, addressing challenges such as intellectual property concerns, slow adoption in certain regions, and educating healthcare professionals will be crucial for sustained market growth.